Drug Profile
Ebronucimab - AD Pharmaceuticals/Akeso Biopharma
Alternative Names: AK-102Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Akeso Biopharma
- Class Antihyperlipidaemics; Monoclonal antibodies
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Hypercholesterolaemia; Hyperlipoproteinaemia type IIa